To analyze if the observed reduction in tumor vascularity upon Nintedanib treatment impacted cell death, we performed immunfluorescence co-stainings of endothelial cells with CD31 with either areas of cell death with Caspase-3 or hypoxic areas with Pimonidazole (Fig. 2A, C). This evidence concerns the gene CASP3 and neoplasm.